Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03523130 · ClinicalTrials.gov registry record
Application of IV 99mTc-tilmanocept for Imaging of Macrophage-specific Inflammation
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 9
- Enrollment target
NCT03523130: Completed study, sponsored by Massachusetts General Hospital.
NCT03523130 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03523130 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate uptake of intravenously administered 99mTc-tilmanocept using single photon emission computed tomography (SPECT/CT) scanning in individuals with HIV and individuals without HIV.
Interventions
- DIAGNOSTIC_TEST Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-05-03 |
| Est. Completion | 2020-10-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03523130
The ClinicalTrials.gov registry entry for NCT03523130 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Imaging is the first listed.
NCT03523130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03523130 about?
NCT03523130 is a clinical study titled "Application of IV 99mTc-tilmanocept for Imaging of Macrophage-specific Inflammation". The purpose of this study is to evaluate uptake of intravenously administered 99mTc-tilmanocept using single photon emission computed tomography (SPECT/CT) scanning in individuals with HIV and individuals without HIV.
What is the current status of trial NCT03523130?
This trial is currently completed. The enrollment target is 9 participants. The study started on 2018-05-03. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT03523130?
The interventions under investigation include: Imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03523130?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.